Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Budnik

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
International Journal of Molecular Sciences|March 14, 2026
Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous FemalesEinat Avishai, Rima Dardik, Linda Rubinstein, et al.
Acta Haematologica|March 16, 2025
Hematological Evaluation and Management of Menorrhagia in Adolescents: Lessons from Adolescent Heavy Menstrual Bleeding ClinicsMarganit Benish, Adi Shitrit Yarhi, Ivan Budnik, et al.
Journal of Clinical Medicine|October 13, 2021
Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with EmicizumabSarina Levy-Mendelovich, Tami Brutman-Barazani, Ivan Budnik, et al.
Blood Cells, Molecules & Diseases|July 10, 2017
Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitorsTami Livnat, Ivan Budnik, Sarina Levy-Mendelovich, et al.
Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomesSarina Levy-Mendelovich, Nitzan Atia, Ivan Budnik, et al.
International Journal of Molecular Sciences|August 27, 2021
Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients-Lessons from Wide Genome AnalysesRima Dardik, Einat Avishai, Shadan Lalezari, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 17, 2021
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world dataMudi Misgav, Tami Brutman-Barazani, Ivan Budnik, et al.
British Journal of Haematology|January 24, 2024
Emicizumab prophylaxis in infants: Single-centre experienceSarina Levy-Mendelovich, Noa Greenberg-Kushnir, Ivan Budnik, et al.
Current Eye Research|June 21, 2017
Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal DiseasesRita Ehrlich, Alon Zahavi, Ruth Axer-Siegel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 23, 2021
Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoringAssaf A Barg, Ivan Budnik, Einat Avishai, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
International Journal of Molecular Sciences|March 14, 2026
Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous FemalesEinat Avishai, Rima Dardik, Linda Rubinstein, et al.
Acta Haematologica|March 16, 2025
Hematological Evaluation and Management of Menorrhagia in Adolescents: Lessons from Adolescent Heavy Menstrual Bleeding ClinicsMarganit Benish, Adi Shitrit Yarhi, Ivan Budnik, et al.
Journal of Clinical Medicine|October 13, 2021
Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with EmicizumabSarina Levy-Mendelovich, Tami Brutman-Barazani, Ivan Budnik, et al.
Blood Cells, Molecules & Diseases|July 10, 2017
Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitorsTami Livnat, Ivan Budnik, Sarina Levy-Mendelovich, et al.
Research and Practice in Thrombosis and Haemostasis|August 4, 2023
Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomesSarina Levy-Mendelovich, Nitzan Atia, Ivan Budnik, et al.
International Journal of Molecular Sciences|August 27, 2021
Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients-Lessons from Wide Genome AnalysesRima Dardik, Einat Avishai, Shadan Lalezari, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 17, 2021
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world dataMudi Misgav, Tami Brutman-Barazani, Ivan Budnik, et al.
British Journal of Haematology|January 24, 2024
Emicizumab prophylaxis in infants: Single-centre experienceSarina Levy-Mendelovich, Noa Greenberg-Kushnir, Ivan Budnik, et al.
Current Eye Research|June 21, 2017
Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal DiseasesRita Ehrlich, Alon Zahavi, Ruth Axer-Siegel, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 23, 2021
Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoringAssaf A Barg, Ivan Budnik, Einat Avishai, et al.
Pageof 7